1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/9077
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFroudarakis, M.en
dc.contributor.authorHatzimichael, E.en
dc.contributor.authorKyriazopoulou, L.en
dc.contributor.authorLagos, K.en
dc.contributor.authorPappas, P.en
dc.contributor.authorTzakos, A. G.en
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorDaliani, D.en
dc.contributor.authorPapandreou, C.en
dc.contributor.authorBriasoulis, E.en
dc.date.accessioned2015-11-24T16:46:30Z-
dc.date.available2015-11-24T16:46:30Z-
dc.identifier.issn1879-0461-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9077-
dc.rightsDefault Licence-
dc.titleRevisiting bleomycin from pathophysiology to safe clinical useen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.critrevonc.2012.12.003-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/23312772-
heal.identifier.secondaryhttp://ac.els-cdn.com/S1040842812002491/1-s2.0-S1040842812002491-main.pdf?_tid=9bbc0a3a-4075-11e3-9cf1-00000aacb362&acdnat=1383036142_0d0e1a8461bda219572d1d088dd18a0f-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2013-
heal.abstractBleomycin is a key component of curative chemotherapy regimens employed in the treatment of curable cancers, such as Hodgkin lymphoma (HL) and testicular germ-cell tumours (GCT), yet its use may cause bleomycin-induced lung injury (BILI), which is associated with significant morbidity and a mortality rate of 1-3%. Diagnosis of BILI is one of exclusion and physicians involved in the care of HL and GCT patients should be alerted. Pharmacogenomic studies could contribute towards the identification of molecular predictors of bleomycin toxicity on the aim to optimize individual use of bleomycin. We review all existing data on bleomycin's most recent integrated chemical biology, molecular pharmacology and mature clinical data and provide guidelines for its safe clinical use.en
heal.publisherElsevieren
heal.journalNameCrit Rev Oncol Hematolen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
File Description SizeFormat 
Froudarakis-2013-Revisiting bleomycin.pdf1.27 MBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons